COMPANY STATEMENT

Updated July 2020

BD Statement on COVID-19 (Coronavirus)

BD is closely monitoring the COVID-19 (coronavirus) situation across the world and guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and health officials in a variety of affected countries to protect the health and safety of BD employees while ensuring continued availability of BD’s critical medical devices at this unprecedented time.

Status of BD operations and supply chain

BD manufactures and sources product from multiple locations around the world. All of our global manufacturing and distribution centers are operational at this time, with the vast majority of critical-to-COVID sites operating at or near full capacity. In countries where local governments have imposed stricter "lockdown” measures to slow the spread of coronavirus, BD's operations continue to operate with measures in place to ensure business continuity and minimize risk of disruption to our customers.

In addition, BD continues to work closely with our key suppliers around the world that provide raw materials and components to BD manufacturing plants. We have implemented business continuity measures to mitigate the risk of potential supplier disruption, including partnering with local governments to seek “essential business” exemptions for key suppliers where necessary. For the vast majority of products considered critical-to-COVID, BD continues to have sufficient raw material and component inventory.

BD is making every effort to ensure product is transported to distributors and customers as quickly and efficiently as possible. We are actively monitoring our global logistics and transportation network, taking necessary actions to work around global capacity and border constraints to minimize the risk of any customer delays.

We are continuing to enforce our pandemic protocols and measures within our facilities to maintain the health and safety of our associates while ensuring business continuity for our customers.

Product availability

Across BD, we are closely monitoring inventory and customer ordering to ensure supply continuity. For U.S. customers, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation.

Business continuity planning

BD has business continuity plans for these types of situations. If a product or raw material is deemed at risk, BD will adopt numerous contingency plans including seeking alternative suppliers, expediting shipments, redeploying raw materials and/or finished goods from other parts of the BD network and placing at-risk products on order review to prevent hoarding behavior. BD also institutes preventative pandemic precautions
at facilities to protect employees, including increasing cleaning protocols, implementing temperature screenings for on-site employees, encouraging work-from-home for all employees who are able, suspending travel and group meetings, limiting on-site visitors, and regularly educating employees about good hygiene and health practices, including social distancing, self-quarantining and handwashing.

**Supporting global response**

As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus – from our diagnostic offerings to identify COVID-19, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. Specifically, BD:

- [Launched a portable, rapid point-of-care antigen test](https://www.bdx.com/newsroom/2020/03/02/bd-launches-portable-rapid-point-of-care-antigen-test-to-detect-covid-19.html) to detect SARS-CoV-2 in 15 minutes, dramatically expanding access to COVID-19 testing.
- Received [CE mark and Emergency Use Authorization (EUA) from the FDA for an additional molecular diagnostics test for COVID-19](https://www.bdx.com/newsroom/2020/03/10/bd-receives-ce-mark-and-emergency-use-authorization-for-new-antigen-test-for-covid-19.html) that can return results in two to three hours, helping to increase the availability of tests around the world.
- Partnered with BioGX to [launch a new diagnostic test that will enable hospitals to screen for COVID-19 on site](https://www.bdx.com/newsroom/2020/03/12/bd-launches-new-high-throughput-covid-19-diagnostics-test-and-instant-screening-application.html) and get results in under three hours.
- Collaborating with peers from across the industry, HHS, FDA and private partners to identify and validate additional swab types as well as transport medium options in order to expand capacity and alternative collection methods.
- Announced the [launch of the Prevention Course in HAI Knowledge and Control](https://www.bdx.com/newsroom/2020/03/12/bd-launches-new-high-throughput-covid-19-diagnostics-test-and-instant-screening-application.html), developed independently by the Society for Healthcare Epidemiology of America (SHEA) and supported in full by an educational grant from BD.
- Worked closely with the governments in Canada and the United Kingdom, which are among the first countries to order enough injection devices to inoculate their entire populations, once a vaccine is approved. BD is actively engaging with the U.S. government to determine how to best partner to fulfill the promise of Operation Warp Speed, and advising all governments around the world about the need to act with urgency.

In addition, BD is deploying $1.1 million in cash and product donations to seven non-profit organizations – Direct Relief, the International Medical Corps, Americares, the World Health Organization-United Nations Foundation COVID-19 Solidarity Response Fund, Project HOPE, the CDC Foundation and the Wuhan Red Cross – to advance their work to contain COVID-19, support healthcare workers and treat patients in countries throughout the world.

For more on BD’s response efforts, visit our [video library](https://www.bdx.com/newsroom/2020/03/12/bd-launches-new-high-throughput-covid-19-diagnostics-test-and-instant-screening-application.html).